Robust Immune Response Seen in Mix And Match Vaccine Study

Mixing and matching the coronavirus vaccines made by Pfizer-BioNTech and AstraZeneca-Oxford generates a “robust” immune response against the virus, a study led by Oxford University has found.

The researchers are doing all kinds of study that is possible with the two vaccines. A better immunity response had been noted. The prime shot, along with the booster shot can be really helpful to the immune system, but it had proven to be even better if the two shots are different kinds of the vaccine.

The most immune response that they have gotten is even when the Oxford-AstraZeneca shot followed by the Pfizer-BioNTech vaccine.

Robust Immune Response Seen in Mix And Match Vaccine Study

“Both ‘mixed’ schedules (Pfizer-BioNTech followed by Oxford-AstraZeneca, and Oxford-AstraZeneca followed by Pfizer-BioNTech) induced high concentrations of antibodies against the SARS-CoV2 spike IgG protein when doses were administered four weeks apart,” the researchers noted.

“This means all possible vaccination schedules involving the Oxford-AstraZeneca and Pfizer-BioNTech vaccines could potentially be used against Covid-19.”

This might open a lot of new doors and can be proved helpful to humanity too. It truly is amazing that the work of mixing the two vaccines can produce such strong results.

A lot of people are skeptical about this, but we need to understand that health experts and researchers are doing their best to provide the human race with immunity against this virus.

No announcement had yet been made about the use of this method in real life, but if everything goes according to plan, then that might be brought into practice really soon. We need to keep patience and wait and watch. We are sure it would reap good results!


An Advantageous Mismatch

Sweden’s national health registers contain information on vaccination and COVID-19 testing and treatment, therefore epidemiologist Peter Nordström from Ume University and his co-authors analysed this data.

A mixed vaccination schedule reduced the risk of symptomatic infection by 68%, whereas the AstraZeneca 2-dose immunisation reduced the risk by 50% among the 430,000 persons studied4.

Nordström asserts that these and other data show that the heterologous regimens are superior to the standard treatment of AstraZeneca in two equal doses.

This result is consistent with that of an identical analysis5 conducted in Denmark, which, like Sweden, maintains a comprehensive national health and vaccination registry. In April, Denmark stopped using the AstraZeneca vaccination entirely.

According to research conducted by epidemiologist Mie Agermose Gram of the State Serum Institute in Copenhagen and colleagues, a single dose of AstraZeneca followed by a single dose of Pfizer-BioNTech was 88% effective at preventing SARS-CoV-2 infection, with results similar to those obtained with two doses of Pfizer. Their research has not yet been reviewed by other academics.

There is No Need for Brand Devotion.

Two doses of an mRNA vaccine may not be as beneficial as a combination of other regimens, according to one study.

Thierry Walzer, an immunologist at France’s Inserm and the University of Lyon, and his co-authors analysed data from 2,512 healthcare professionals who received a mix of AstraZeneca and Pfizer vaccinations, and from over 10,000 who received two doses of the latter.

Infectiousness with SARS-CoV-2 was demonstrated to be 50% lower in the combination group compared to the two-dose Pfizer6 group.